Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest

О. И. Лисицына, E. G. Khilkevich
In: Medical Council · 2019 · pp. 39–44 · doi:10.21518/2079-701x-2019-7-39-44 · W2942588303
article OA: diamond CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Estradiol valerate and dienogest combined oral contraceptives effectively inhibit ovulation, control cycles, and reduce menstrual blood loss, proving useful for contraception and menorrhagia therapy in women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This Russian-language overview summarizes therapeutic options of a combined oral contraceptive containing estradiol valerate and dienogest, drawing on previously published phase III trials and other studies across topics such as contraception, heavy menstrual bleeding, hormone-withdrawal symptoms, metabolic/hemostatic effects, endometrial safety, and quality-of-life outcomes, including work productivity in heavy menstrual bleeding. The key reported findings across the cited literature are that estradiol valerate/dienogest has documented efficacy and safety for its contraceptive use and for heavy menstrual bleeding endpoints, with additional attention to endometrial safety and various non-contraceptive outcomes; specific studies also address feasibility for office hysteroscopic polypectomy preparation and certain recurrence-prevention contexts. As a narrative review rather than a new experimental study, it has the limitation that it does not provide a unified pooled analysis and instead depends on heterogeneity across the included sources. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Taking into account that the frequency of abortions in Russia today remains quite high, the strategy of fertility regulation through the provision of contraceptive advice to women of various ages comes to the fore. It has been proven that combined oral contraceptives are the most effective method of preventing unwanted pregnancies. An innovative combination of oral contraceptives containing estradiol valerate (EV) and dienogest (DNG) dynamically provides effective inhibition of ovulation and sufficient cycle control. DNG/EV has high efficacy, acceptability and tolerability and can be successfully used in sexually active women in need of contraception, regardless of their age. Like any modern contraceptive, this drug possesses a whole arsenal of pronounced therapeutic possibilities, which can be used in real clinical practice. In addition, the combination of EV and DNG is highly effective in the therapy of menorrhagia. The percentage of patients who had successful treatment and resulted in a decrease in menstrual blood loss was high. The effectiveness of the drug is confirmed by the bleeding of withdrawal at the end of the first treatment cycle and continues to increase gradually with further administration.
Full text 11,745 characters · extracted from oa-doi-fallback · click to expand
Обзор терапевтических возможностей комбинированного орального контрацептива, содержащего эстрадиола валерат и диеногест https://doi.org/10.21518/2079-701X-2019-7-39-44 Аннотация Об авторах О. И. ЛисицынаРоссия Лисицына Ольга Игоревна – ординатор. 117997, Россия, г. Москва, ул. Академика Опарина, д. 4. Е. Г. Хилькевич Россия Хилькевич Елена Григорьевна – д.м.н., врач акушер-гинеколог хирургического отделения. 117997, Россия, г. Москва, ул. Академика Опарина, д. 4. Список литературы 1. Sitruk-Ware R. and Nath A. Metabolic effects of contraceptive steroids. Rev. Endocr. Metab. Disord.2011;12(2):63–75. 2. Прилепская В.Н., Межевитинова Е.В., Иванова Е.А., Сасунова Р.А., Набиева К.Р., Летуновская А.Б. Эволюция гормональной контрацепции. Меди-цинский совет.2011;7–8:61–64. [Prilepskaya V.N., Mezhevitinova E.V., Ivanova E.A., Sasunova R.A., Nabieva K.R., Letunovskaya A.B. Hormonal contraception evolution. Medical Council [Medicinskij sovet]. 2011;7–8:61–64.] (In Russ.) 3. Graziottin A. The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval. Eur. J. Contracept. Reprod. Heal. Care. 2016;21:93–105. 4. Yu Q., Huang Z., Ren M., Chang Q., Zhang Z., and Parke S. Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: A multicenter, open-label, uncontrolled phase iii study. Int. J. Womens. Health. 2018;10:257–266. 5. Palacios S., Wildt L., Parke S., Machlitt A., Römer T., and Bitzer J. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial. Eur. J. Obstet. Gynecol. Reprod. Biol.2010;149(1):57–62. 6. Barnett C., Hagemann C., Dinger J., Do Minh T., and Heinemann K. Fertility and combined oral contraceptives – unintended pregnancies and planned pregnancies following oral contraceptive use – results from the INAS-SCORE study. Eur J Contracept Reprod Heal. Care.2017;22(1):17–23. 7. Dinger J., Do Minh T. and Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94(4):328–339. 8. Raps M., Rosendaal F., Ballieux B., Rosing J., Thomassen S., Helmerhorst F. and van Vliet H. Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: A randomized controlled trial. J. Thromb. Haemost.2013;11(5):855–861. 9. Klipping C., Duijkers I., Parke S., Mellinger U., Serrani M., and Junge W. Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive. Drugs R. D., 2011;11(2):159–170. 10. Линников В.И., Бондаренко Н.И. Влияние оральных контрацептивов на систему гемостаза и метаболизм липидов. Таврический медико-биологический вест-ник.2011;14(3:1:55):141–143. [Linnikov V.I., Bondarenko N.I. Influence of oral contraceptives on hemostasis system and lipid metabolism.Taurida medical biological bulletin [Tavricheskij mediko-biologicheskij vestnik].2011;14(3:1:55):141–143.] (In Russ.) 11. Bitzer J., Parke S., Roemer T., and Serrani M. Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest. Int J Womens Heal. 2011;3:127–32. 12. Jensen J., Parke S., Mellinger U., Serrani M., and Mabey R. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/ dienogest versus ethinylestradiol/norgestimate. Eur J Contracept Reprod Heal. Care., 2013;18(4):274–283. 13. Macìas G., Merki-Feld G.S., Parke S., Mellinger U., and Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: Results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J. Obstet. Gynaecol. (Lahore)., 2013;33(6):591–6. 14. Gallo M., Nanda K., Grimes D., Lopez L., and Schulz K. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev.2013;1(8):CD003989. 15. Briggs P., Serrani M., and Vogtländer K. Continuation rates , bleeding profile acceptability , and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real. Int. J. Women’s Heal.2016;8:477–487. 16. Nappi R.E., Serrani M., and Jenen J.T. Noncontraceptive benefits of the estradiol valerate/dienogest combined oral contraceptive: A review of the literature. Int. J. Womens. Health. 2014;6(1):167–175. 17. De Seta F., Restaino S., Banco R., Conversano E., De Leo R., Tonon M., Maso G., Barbati G., and Lello S. Effects of estroprogestins containing natural estrogen on vaginal flora. Gynecol. Endocrinol.2014;30(11):830–835. 18. Юцковская Я.А., Дворянинова И.Е., Золотова О.И., Суханова А.С. Возможности улучшения качества кожи у женщин. Результаты клинического исследования влияния препарата клайра на кожу женщин разных возрастных групп. Проблемы репродукции. 2014;5:43–51. [Yutskovskaya Ya.A., Dvoryaninova I.E., Zolotova O.I., Sukhanova A.S. Possibilities to improve skin quality in women. Results of clinical study of the effect of the Qlaira drug on the skin of women of different age groups. Reproduction problems [Problemy reprodukcii]. 2014;5:43–51.] (In Russ.) 19. Di Carlo C., Gargano V., De Rosa N., Tommaselli G.A., Sparice S., and Nappi C. Effects of estradiol valerate and dienogest on quality of life and sexual function according to age. Gynecol. Endocrinol.2014;30(12):925–928. 20. Paoletti A.M., Lello S., Di Carlo C., Orrù M., Malune M.E., Neri M., Pilloni M., Zedda P., Dalterio M.N., Motzo C., Melis G.B., and Cagnacci A. Effect of Estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: A prospective one-year evaluation. Gynecol. Endocrinol.2016;32(1):61–64. 21. De Leo V., Fruzzetti F., Musacchio M.C., Scolaro V., Di Sabatino A., and Morgante G. Effect of a new oral contraceptive with estradiol valerate/dienogest on carbohydrate metabolism. Contraception. 2013;88:364–368. 22. Grandi G., Piacenti I., Volpe A., and Cagnacci A. Modification of body composition and metabolism during oral contraceptives containing non-androgenic progestins in association with estradiol or ethinyl estradiol. Gynecol Endocrinol.2014;30(9):676–80. 23. Di Carlo C., Gargano V., Sparice S., Tommaselli G.A., Bifulco G., and Nappi C. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol. 2013;29(12):1048–1050. 24. Granese R., Perino A., Calagna G., Saitta S., De Franciscis P., Colacurci N., Triolo O., and Cucinella G. Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis : a multi-center randomized trial. Acta Obs. Gynecol Scand.2015;94(6):637–45. 25. Grandi G., Xholli A., Napolitano A., Palma F., and Cagnacci A. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: A patient-preference prospective 24-week pilot study. Reprod. Sci.2015;22(5):626–632. 26. Семыкин А.Н., Гололобова В.А., Чуприна Н.Г., Пастушкова О.В., Минькова Е.В. Эффективность противорецидивной терапии комбинированным оральным контрацептивом клайра после лапароскопического удаления кист яичников. Проблемы репродукции, 2013;5:47–48. [Semykin A.N., Gololobova V.A., Chuprina N.G., Pastushkova O.V., Min’kova E.V. Efficiency of anti-relapsing therapy with combined oral contraceptive Qlaira after laparoscopic removal of ovarian cysts.Reproduction problems [Problemy reprodukcii], 2013;5:47-48.] (In Russ.) 27. Михельсон А.Ф., Феоктистова Т.Е., Лебеденко Е.Ю., Михельсон А.А., Синельник Е.А., Акименко М.А. Влияние комбинации эстрадиола валерата и диеногеста на частоту рецидивов гормончувствительных полипов эндометрия. Доктор.Ру, 2016;124(7):27–31. [Mikhelson A.F., Feoktistova T.E., Lebedenko E.Yu., Mikhelson A.A., Sinelnik E.A., Akimenko M.A. Influence of the combination of estradiol valerate and dienogest on the frequency of recurrence of hormone-sensitive endometrial polypes. Doctor.ru, 2016;124(7):27-31.] (In Russ.) 28. Bifulco G., Di Spiezio Sardo A., De Rosa N., Greco E., Spinelli M., Di Carlo C., Tommaselli G.A., and Nappi C. The use of an oral contraceptive containing estradiol valerate and dienogest before office operative hysteroscopy: A feasibility study. Gynecol. Endocrinol., 2012;28(12):949–955. 29. Cicinelli E., Pinto V., Quattromini P., Fucci M.R., Lepera A., Mitola P.C., Cicinelli M.V., Annarita F., and Tinelli R. Endometrial Preparation With Estradiol Plus Dienogest (Qlaira) for Office Hysteroscopic Polypectomy: Randomized Pilot Study. J. Minim. Invasive Gynecol., 2012;19(3):356–359. 30. Леонидова Т.Н., Микова В.Н. Гормональная контрацепция и маммологические риски. Доктор.Ру, 2016;120(3):15–17. [Leonidova T.N., Mikova V.N. Hormonal contraception and mammological risks. Doctor.ru,2016;120(3):15-17.] (In Russ.) 31. Vetvik K.G., MacGregor E.A., Lundqvist C., and Russell M.B. Self-reported menstrual migraine in the general population. J. Headache Pain, 2010;11:87–92. 32. Nappi R.E., Terreno E., Sances G., Martini E., Tonani S., Santamaria V., Tassorelli C., and Spinillo A. Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM). Contraception. 2013;88(3):369–375. 33. Доброхотова Ю.Э., Ибрагимова Д.М., Гришин И.И. Меноррагия: есть ли пути решения? Медицинский совет., 2016;12:12–13. [Dobrokhotova Yu.E., Ibragimova D.M., Grishin I.I. Menorrhagia: are there any ways of solution? Medical Council [Medicinskij sovet], 2016;12:12-13.] (In Russ.) 34. Jensen J.T., Parke S., Mellinger U., MacHlitt A., Fraser I.S. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: A randomized controlled trial. Obstet. Gynecol.2011;117(4):777–87. 35. Yu Q., Zhou Y., Suturina L., Jaisamrarn U., Lu D., Parke S. Efficacy and Safety of Estradiol Valerate/Dienogest for the Management of Heavy Menstrual Bleeding: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Clinical Trial. J. Women’s Heal.2018;27(10):1225–1232. 36. Fraser I.S., Parke S., Mellinger U., MacHlitt A., Serrani M., Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: Pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur. J. Contracept. Reprod. Heal. Care. 2011;16(4):258–69. 37. Fraser I.S., Römer T., Parke S., Zeun S., Mellinger U., MacHlitt A., Jensen J.T. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: A randomized, double-blind Phase III trial. Hum. Reprod.2011;26(10):2698–708. 38. Wasiak R., Filonenko A., Vanness D.J., Law A., Jeddi M., Wittrup-Jensen K.U., Stull D.E., Siak S., Jensen J.T. Impact of Estradiol Valerate/Dienogest on Work Productivity and Activities of Daily Living in Women with Heavy Menstrual Bleeding. J. Women’s Heal.2013;22(4):378–384. Рецензия Для цитирования: Лисицына ОИ, Хилькевич ЕГ. Обзор терапевтических возможностей комбинированного орального контрацептива, содержащего эстрадиола валерат и диеногест. Медицинский Совет. 2019;(7):39-44. https://doi.org/10.21518/2079-701X-2019-7-39-44 For citation: Lisitsyna OI, Khilkevich EG. Overview of the therapeutic possibilities of combined oral contraceptive containing estradiol valerate and dienogest. Meditsinskiy sovet = Medical Council. 2019;(7):39-44. (In Russ.) https://doi.org/10.21518/2079-701X-2019-7-39-44 JATS XML

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (31)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK